Sarah Boyce
CIK 1629383 · President and CEO · last filed 2026-06-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$4.66M
Companies
9
Total Filings
67
Lifetime Open-Market Net
-$33.85M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CTNM | Director | — | $14.16 | — | $0 | 3 | 2026-06-26 |
| Avidity Biosciences, Inc. (RNAM) Delisted | President and CEO | 0 | — | — | $0 | 1 | 2026-02-27 |
| RNA | President and CEO | 277,000 | $11.49 | $3.18M | -$33.09M | 27 | 2026-01-23 |
| OABIW | Director | 104,381 | $0.08 | $8.7K | $101.4K | 5 | 2024-06-21 |
| LGND | Director | 2,892 | $296.28 | $856.8K | $0 | 5 | 2022-11-03 |
| Bruker Cellular Analysis, Inc. (BLI) Delisted | Director | 1,400 | $1.20 | $1.7K | -$611.3K | 2 | 2021-05-18 |
| AKCEA THERAPEUTICS, INC. (AKCA) Delisted | President | 19,888 | — | — | -$42.8K | 4 | 2019-07-17 |
| IONS | Chief Business Officer | 11,127 | $55.30 | $615.3K | -$212.8K | 8 | 2018-01-17 |
| IONIS PHARMACEUTICALS INC (ISIS) Delisted | Chief Business Officer | — | — | — | $0 | 2 | 2015-01-20 |
Recent Filings · Page 3 of 7
67 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-20 | RNA | Mixed | +92,926 | -$1.26M | EDGAR |
| 2024-06-14 | RNA | Mixed | — | -$11.22M | EDGAR |
| 2024-06-13 | Avidity Biosciences, Inc. (RNAM) Delisted | Notice (144) | −200,000 | -$7.67M | EDGAR |
| 2024-06-12 | Avidity Biosciences, Inc. (RNAM) Delisted | Notice (144) | −100,000 | -$2.89M | EDGAR |
| 2024-06-05 | RNA | Mixed | — | -$733.1K | EDGAR |
| 2024-06-04 | Avidity Biosciences, Inc. (RNAM) Delisted | Notice (144) | −84,000 | -$2.26M | EDGAR |
| 2024-05-07 | RNA | Mixed | — | -$680.3K | EDGAR |
| 2024-04-23 | OABIW | Grant (A) | +39,628 | $0 | EDGAR |
| 2024-04-03 | RNA | Mixed | — | -$700.2K | EDGAR |
| 2024-03-12 | Avidity Biosciences, Inc. (RNAM) Delisted | Notice (144) | −84,000 | -$1.77M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.